CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate.
  
  LEARNING OBJECTIVES

  • Appraise published research and current guidelines for the optimal management of prostate cancer for patients with biochemical recurrence after local treatment, and counsel appropriate candidates regarding the potential benefits of systemic therapy.
  • Evaluate published research supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with cytotoxic therapy, secondary hormonal therapy or combinations of these for metastatic hormone-sensitive prostate cancer, and integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for metastatic CRPC (mCRPC), considering patient age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess the available research supporting the use of PARP inhibitor monotherapy for mCRPC with a homologous recombination repair (HRR) gene alteration, and discern how to optimally incorporate these agents into current treatment algorithms.
  • Develop an understanding of the rationale for, available and emerging data with and ongoing research evaluating PARP inhibitors in combination with androgen receptor-targeted therapy, and consider the potential role of these novel regimens for patients with and without HRR gene mutations.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Emmanuel S Antonarakis, MD
  Clark Endowed Professor of Medicine
  Division of Hematology, Oncology and Transplantation
  University of Minnesota
  Minneapolis, Minnesota
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Sanofi; Consulting Agreements: AIkido Pharma Inc, Blue Earth Diagnostics, Clovis Oncology, CM Propel, EcoR1 Capital LLC, Exact Sciences Corporation, Foundation Medicine, KeyQuest Health, Orion Corporation, Tempus; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Clovis Oncology; Patent Holder: QIAGEN; Nonrelevant Financial Relationship: Ismar Healthcare NV, Projects in Knowledge.
  
  Prof Karim Fizazi, MD, PhD
  Head of Service and Full Professor
  Institut Gustave Roussy
  University of Paris Saclay
  Villejuif, France
  
  Advisory Board (Honoraria to Me): CureVac, Orion Corporation; Advisory Board or Speaking Engagements (Honoraria Provided to My Institution): Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi.
  
  Maha Hussain, MD, FACP, FASCO
  Genevieve Teuton Professor of Medicine
  Division of Hematology/Oncology
  Deputy Director
  Robert H Lurie Comprehensive Cancer Center
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  Contracts for Clinical Trials with Northwestern University: Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group; Honoraria — Advisory Boards: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Convergent Therapeutics Inc, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Tempus; Invited Speaker by International Specialty Societies (Brazil, India, Israel, Korea, Malaysia): Astellas, AstraZeneca Pharmaceuticals LP; Nonrelevant Financial Relationship (Educational Lectures): Clinical Care Options, Great Debates and Updates in GU Oncology, Medscape, Medscape Zero, MJH Life Sciences, Precisca.
  
  Matthew R Smith, MD, PhD
  Claire and John Bertucci Endowed Chair in Genitourinary Cancers
  Professor of Medicine
  Harvard Medical School
  Director, Genitourinary Malignancies Program
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research (to Institution): Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.
  
  MODERATOR
  
  Alan H Bryce, MD
  Director, Mayo Clinic Comprehensive Cancer Center in Arizona
  Chair, Division of Hematology and Medical Oncology
  Mayo Clinic
  Phoenix, Arizona
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Gilead Sciences Inc, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis; Contracted Research: Janssen Biotech Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi.
  
  Release date: March 2023
  Expiration date: March 2024